Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabedersen - Autotelic/Oncotelic

Drug Profile

Trabedersen - Autotelic/Oncotelic

Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisense

Latest Information Update: 16 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antisense Pharma
  • Developer Autotelic; Oncotelic
  • Class Antineoplastics; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Malignant melanoma; Pancreatic cancer
  • Preclinical Ovarian cancer
  • No development reported Colorectal cancer
  • Discontinued Anaplastic astrocytoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Sep 2017 Preclinical trials in Pancreatic cancer, Ovarian cancer, Glioblastoma and Malignant melanoma (Combination therapy) in USA (IV)
  • 31 Aug 2017 Efficacy and pharmacokinetic data from a phase I/II trial in Pancreatic cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top